文献速递临床试验与 GCP

个性化暴露与体验采样法反馈对比常规暴露治疗强迫症:一项随机对照试验的研究方案

Personalized exposure and experience sampling method feedback versus exposure as usual for obsessive-compulsive disorder: a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-01-12

主要结局为强迫症状严重程度,次要结局包括生活质量、抑郁与焦虑状态,并探讨自我效能与经验性回避的中介作用。

要点

  • 个性化ERP通过智能手机应用在实时实地情境中提供,并基于ESM数据识别触发因素与保护因素。
  • 研究设20周每周1次治疗,两组分别为常规ERP与个性化ERP,随访至1年。
  • 将检验自我效能与经验性回避是否中介治疗效果。

核心结论

  • 该随机对照试验首次评估通过视频通话提供ERP及使用ESM干预对强迫症症状严重程度的影响。

研究设计与样本

  • 随机对照试验,两组分别为常规ERP与个性化ERP,每组每周1次共20次治疗。
  • 在基线(T0)、治疗5周(T1)、10周(T2)、15周(T3)、20周后测(T4)、6周随访(T5)、3个月随访(T6)、6个月随访(T7)及1年随访(T8)进行重复测量。

主要发现

  • 采用多水平混合模型分析治疗效果的差异以及生活质量、抑郁症状和焦虑状态的差异。
  • 使用Preacher和Hayes宏及bootstrapping方法评估自我效能与经验性回避变化对后续治疗效果的可能中介效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with obsessive-compulsive disorder (OCD) suffer from repetitive fearful intrusions which they try to neutralize by performing compulsions. OCD is considered to be the most resistant anxiety disorder with a remission rate of only 53% after a year of an evidence-based treatment. Therefore, it remains an obligation to develop and investigate more effective treatment interventions. This study aims to compare personalized exposure with response prevention (ERP) using experience sampling methodology-based feedback to ERP as usual in patients with OCD. Personalized exposure will be provided screen-to-screen in an ecologically valid (real time and real place) context by means of a smartphone application. This app will also be used to collect both objective and subjective data by means of experience sampling methodology (ESM). This ESM data will be used to identify triggers and protective factors for symptom severity, provide personalized feedback and optimize the effect of ERP. The primary goal of this RCT is to compare the effectiveness of personalized ERP to ERP as usual in the traditional context of a therapist's room in patients with OCD in OCD symptom severity, as well as differences in quality of life, depressive symptoms and anxiety states. Since both self-efficacy and experiential avoidance are known to influence symptom severity in OCS, a secondary goal is to examine if a possible treatment effect is mediated by self-efficacy or experiential avoidance. METHODS: This study involves a randomized controlled trial with 20 weekly sessions by 2 groups (ERP as usual versus personalized ERP), repeated measurements at baseline (T0), 5 weeks of treatment (T1), 10 weeks of treatment (T2), 15 weeks of treatment (T3), posttest at 20 weeks (T4), 6 weeks follow-up (T5), 3 months follow-up (T6), 6 months follow-up (T7) and a year follow-up (T8). A hundred and sixty patients with an OCD diagnosis according to DSM-5 criteria will participate. Half of the group will receive exposure with response prevention as usual, the other half will receive personalized exposure with response prevention with a smartphone application and personalized feedback sessions based on experience sampling data. Multilevel mixed modelling analysis will be used to investigate differences in treatment effect, as well as differences in quality of life, depressive symptoms and anxiety states. We will use the macro of Preacher and Hayes and apply bootstrapping methods to assess the possible mediating effect of changes in self-efficacy and experiential avoidance on subsequent treatment effects. DISCUSSION: This randomized controlled trial is the first to assess the influence of delivering ERP through video-calling and the use of an ESM intervention on the symptom severity of OCD. Since the global pandemic COVID-19, the use of video-calling to deliver psychological treatments has become more common, increasing the relevance of this study. TRIAL REGISTRATION: ICTRP Trial NL8254. Registered on 2019-12-24.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hoogerwerf E, Greeven A, Goekoop R, et al. Personalized exposure and experience sampling method feedback versus exposure as usual for obsessive-compulsive disorder: a study protocol for a randomized controlled trial. Trials. 2024. PMID: 38217045. doi:10.1186/s13063-023-07780-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。